Cover Image Eliaz Therapeutics Highlights Selective Galectin-3 Removal in Sepsis, Advances XGAL-3® Program Santa Rosa, United ...
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of ...
Galectin Therapeutics is a Buy as recent FDA alignment de-risks belapectin’s Phase 3 path and clarifies regulatory endpoints.
Newsable Asianet News on MSN
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
Galectin plans to submit the final trial protocol to the FDA in the third quarter of 2026.
Zacks Investment Research on MSN
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH
Galectin Therapeutics GALT shares surged 11.4% on Tuesday after the company announced it had reached alignment with the FDA ...
(RTTNews) - Galectin Therapeutics Inc. (GALT) Friday announced that the U.S. FDA has provided written feedback on its development program for Belapectin, the company's investigational galectin-3 ...
View Galectin Therapeutics Inc. GALT stock quote prices, financial information, real-time forecasts, and company news from CNN.
A start-up called Pectacea is making "solid progress" on a pioneering project that could create a completely new category of heart-healthy foods based on the ability of natural pectins to inhibit a ...
Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal ...
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA
NORCROSS, Ga.--(BUSINESS WIRE)-- Galectin Therapeutics (NAS: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results